Nina Niu Sanford: Small RCT Showing OS Benefit of Chemoradiotherapy plus Immunotherapy vs Observation in Resected GB/EHC
Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared a post on X by Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, adding:
“Small (n=93) RCT showing OS benefit of Chemoradiotherapy + Immunotherapy vs. observation in resected GB/EHC.
How much benefit due to IO vs. RT component? How would outcomes compare to current SOC of djuvant chemo? RT synergy with IO (since 81% R0 resection)?
Much to explore. Hope for coop trial in this space.”
Quoting Akhil Santhosh‘s post:
“Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer
ACCORD: camrelizumab+ cape-RT improves RFS and OS compared to observation in resected GBC and EHCC.”
Title: Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer
Journal: JAMA Oncology
Authors: Han Xiao, Jiansong Ji, Shaoqiang Li, Jiaming Lai, Guangyan Wei, Jian Wu, Wei Chen, Wenxuan Xie, Shutong Wang, Liangliang Qiao, Jianfei Tu, Shunli Shen, Zhenwei Peng
More posts featuring Nina Niu Sanford on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023